{"result": "(\"entity\"<|>MNGIE<|>EVENT<|>MNGIE is a rare mitochondrial disorder characterized by a deficiency in the enzyme thymidine phosphorylase, leading to various metabolic issues.)\n##\n(\"entity\"<|>COENZYME Q 10<|>ORGANIZATION<|>Coenzyme Q 10 is an antioxidant and a vital component of the mitochondrial respiratory chain, evaluated for its effectiveness in mitochondrial diseases.)\n##\n(\"entity\"<|>CREATINE<|>ORGANIZATION<|>Creatine is a substance that has been studied for its potential benefits in improving muscle strength in patients with mitochondrial diseases.)\n##\n(\"entity\"<|>L-CARNITINE<|>ORGANIZATION<|>L-Carnitine is a treatment suggested for patients with primary systemic carnitine deficiency, known for its safety and ability to correct underlying carnitine deficits.)\n##\n(\"entity\"<|>THYMIDINE PHOSPHORYLASE<|>ORGANIZATION<|>Thymidine phosphorylase is an enzyme whose activity is crucial for metabolic processes, particularly in the context of MNGIE.)\n##\n(\"entity\"<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>EVENT<|>Hematopoietic stem cell transplant is a treatment option being explored to correct the enzymatic deficiency in MNGIE.)\n##\n(\"entity\"<|>DIALYSIS<|>EVENT<|>Dialysis is a treatment method that has been used in patients with MNGIE to reduce levels of thymidine and deoxyuridine in circulation.)\n##\n(\"entity\"<|>PLATELET INFUSION<|>EVENT<|>Platelet infusion from healthy donors is a treatment approach attempted in MNGIE to partially restore thymidine phosphorylase activity.)\n##\n(\"relationship\"<|>MNGIE<|>THYMIDINE PHOSPHORYLASE<|>MNGIE is characterized by a deficiency in thymidine phosphorylase, which leads to its metabolic complications.<|>9)\n##\n(\"relationship\"<|>MNGIE<|>HEMATOPOIETIC STEM CELL TRANSPLANT<|>Hematopoietic stem cell transplant is being explored as a potential treatment to correct the enzymatic deficiency in MNGIE.<|>7)\n##\n(\"relationship\"<|>MNGIE<|>DIALYSIS<|>Dialysis has been used as a treatment method to manage symptoms in patients with MNGIE.<|>5)\n##\n(\"relationship\"<|>MNGIE<|>PLATELET INFUSION<|>Platelet infusion has been attempted as a treatment to help manage MNGIE by reducing toxic metabolite levels.<|>5)\n##\n(\"relationship\"<|>COENZYME Q 10<|>MNGIE<|>Coenzyme Q 10 has been evaluated for its potential benefits in treating MNGIE due to its role in mitochondrial function.<|>6)\n##\n(\"relationship\"<|>CREATINE<|>MNGIE<|>Creatine has been studied for its potential to improve muscle strength in patients with MNGIE.<|>6)\n##\n(\"relationship\"<|>L-CARNITINE<|>MNGIE<|>L-Carnitine is suggested for use in patients with MNGIE due to its safety and ability to address carnitine deficiency.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de los pacientes así como de la proteína C reactiva (PCR). El diagnóstico se basa en la medición de la actividad timidina fosforilasa en los leucocitos (ausencia de actividad en los individuos sintomáticos y actividad reducida en los individuos heterocigotos asintomáticos) y en el estudio genético.\n\nEl diagnóstico diferencial debe realizarse con enfermedades que afectan la fosforilación oxidativa y otras enfermedades mitocondriales, la polineuropatía desmielinizante inflamatoria crónica, enfermedades gastrointestinales primarias (dismotilidad gastrointestinal, enfermedad inflamatoria intestinal, enfermedad celíaca, síndrome de colon irritable, trastornos de conducta alimentaria), distrofia muscular congénita por déficit de merosina y las leucodistrofias (enfermedad de Krabbe, adrenoleucodistrofia, enfermedad de Canavan, enfermedad de Alexander, leucoencefalopatía con sustancia blanca evanescente)³.\n\nActualmente, no se dispone de un tratamiento farmacológico efectivo. Las estrategias farmacológicas han ido encaminadas al uso de cofactores de la cadena respiratoria, el tratamiento con antioxidantes, ensayos para la corrección de los déficits bioquímicos secundarios y tratamiento con fármacos para reducir la acumulación de ácido láctico. En muchas ocasiones la evidencia proviene de casos aislados o estudios pequeños. Una revisión sistemática de 2012 identificó 12 ensayos clínicos aleatorizados para evaluar fármacos en las enfermedades mitocondriales sin clara evidencia del uso de ninguna intervención⁴. Pese a que no está bien establecida la efectividad, se recomienda el tratamiento con coenzima Q 10, creatina y L-carnitina.\n---\nLa coenzima Q 10 ha sido evaluada en enfermedades mitocondriales en un estudio doble ciego, cruzado. Se observó un aumento estadísticamente significativo en la escala global de fuerza muscular y un aumento en los niveles séricos de coenzima Q 10⁵. Dado que la coenzima Q 10 es tanto un antioxidante como una parte integral de la cadena respiratoria mitocondrial, el modesto beneficio en el estudio previo y la falta de efectos adversos serios recomiendan el tratamiento en enfermedades mitocondriales, a dosis de 400 mg/día. Respecto al tratamiento con antioxidantes como idebenona, vitamina E, dihidrolipoato no hay datos que evidencien beneficio clínico de su uso.\n\nEn cuanto a la creatina un estudio cruzado controlado con placebo mostró mejoría en algunas variables con un aumento estadísticamente significativo del 20% en la fuerza medida por dinamómetro. Sin embargo, no hubo mejoría en las actividades de la vida diaria⁶. Otro estudio cruzado controlado con placebo que incluye 16 pacientes con enfermedades mitocondriales no encontró ningún beneficio tras 4 semanas de tratamiento con altas dosis de creatina⁷. Dada la evidencia de al menos un ensayo controlado de un beneficio modesto y seguridad en relación con efectos adversos se recomienda a dosis de 10 g durante las primeras dos semanas seguidos de 4 g de mantenimiento. Sin embargo, los calambres suelen ser un problema con altas dosis por lo que se recomienda comenzar con 4.5 g al día dividido en tres dosis y titular según tolerancia con un máximo de 10 g al día. En nuestro paciente no se instauró tratamiento dada la neuropatía severa de base que presentaba. En relación al tratamiento con L-carnitina no hay estudios controlados en pacientes con enfermedad mitocondrial. Sin embargo, se ha visto beneficiosa en pacientes con deficiencia sistémica primaria de carnitina. Se sugiere el tratamiento con carnitina ya que es seguro y corrige el déficit subyacente de carnitina en estos pacientes. Se recomienda una dosis de 1000 mg al día por la mañana⁸.\n\nLos estudios publicados en pacientes con MNGIE tratados con diálisis o infusión de plaquetas de donantes sanos como tratamiento para disminuir los niveles de timidina y deoxiuridina de la circulación, y parcialmente restituir la actividad de la timidin fosforilasa, son poco esperanzadores ya que ambos tratamientos tiene la limitación de ser transitorios. Los tratamientos de reposición enzimáticos están aún en desarrollo. El trasplante alogénico de células hematopoyéticas ofrece la posibilidad de corregir el déficit enzimático, con el propósito de corregir los daños metabólicos al restaurar la actividad de la timidin fosforilasa, disminuyendo las concentraciones plasmáticas de timidina y deoxiuridina. Más de diez pacientes con MNGIE han sido tratados con trasplante de células hematopoyéticas⁹. Sin embargo, este tratamiento presenta un alto porcentaje de mortalidad\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}